^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MAGEC1 expression

    i
    Other names: MAGEC1, MAGE Family Member C1, CT7.1, CT7, Cancer/Testis Antigen Family 7, Member 1, Melanoma-Associated Antigen C1, Melanoma Antigen Family C1, Cancer/Testis Antigen 7.1, MAGE-C1 Antigen, MGC39366, MAGE-C1, Melanoma Antigen Family C, 1
    Entrez ID:
    9947
    almost3years
    PROGNOSTIC SIGNIFICANCE OF DYNAMIC CHANGE OF MAGE-C1/CT7 IN MULTIPLE MYELOMA: TEN YEAR EXPERIENCE FROM A SINGLE CENTER (EHA 2023)
    Our data showed the independent predictive value of peri-ASCT MAGE-C1/CT7 status on PFS in MM patients receiving novel agents and ASCT as frontline treatment. A 2-log decrease of MAGE-C1/CT7 post-induction cycle 2 correlated with peri-ASCT MAGE-C1/CT7-- status, which provided an earlier prognostic marker during treatment.
    Clinical
    |
    MAGEC1 (MAGE Family Member C1)
    |
    MAGEC1 expression
    almost4years
    ASSESSMENT OF THE EFFICACY OF BORTEZOMIB-CONTAINING THERAPY REGIMENS DEPENDING ON MAGE-C1 GENE EXPRESSION IN MULTIPLE MYELOMA PATIENTS. (EHA 2022)
    Induction of remission was carried out by three-component regimens including bortezomib, 30 patients required two or more lines of therapy with lenalidomide or daratumumab. Achievement of ≥PR on bortezomib-containing therapy regimens was documented twice as fast in patients with normal expression of the investigated gene. Further study of the MAGE-C1 gene may allow to determine the tactics of induction therapy already at the diagnostic stage.
    Clinical
    |
    SDC1 (Syndecan 1) • MAGEC1 (MAGE Family Member C1)
    |
    MAGEC1 expression
    |
    lenalidomide • bortezomib • Darzalex (daratumumab)